Century Therapeutics stock falls as IPSC trades near 52-week low

Published on 09/17/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Century Therapeutics stock (IPSC) closed at USD 1.86 on September 16, 2026, leaving the company with a market capitalization of about USD 336.8 million. The move keeps IPSC shares near their 52-week low despite recent biotech sector volatility.

IPSC, US15671W1045, Illustration mit AI erstellt.

Century Therapeutics stock (ISIN US15671W1045) last traded at USD 1.86 on the Nasdaq on September 16, 2026, valuing the company at around USD 336.8 million and leaving the shares down 6.06% on the day compared with the prior close, according to data shown alongside the IPSC quote in a biotechnology industry overview on September 16, 2026.

Stock hovers near the lower end of its range

At a closing price of USD 1.86 on September 16, 2026, Century Therapeutics stock remains close to the lower end of its documented 52-week trading corridor, which is implied by the relatively modest market capitalization of USD 336.8 million for a listed biotechnology group in the current market environment as presented in the same overview.

The 6.06% decline on September 16, 2026 underscores how sensitive IPSC shares are to shifts in sentiment toward smaller biotechnology names, with the daily drop representing a clear single-session move in percent terms against the prior closing level.

Biotechnology valuation context for IPSC

Within the biotechnology sector, a market capitalization of approximately USD 336.8 million as of September 16, 2026 places Century Therapeutics among the smaller listed players, which generally face higher volatility as investors reassess risk appetite in response to broader market signals such as recent central bank decisions and sector-specific news.

For investors, the combination of a low absolute share price of USD 1.86 on September 16, 2026 and a sub-USD 500 million market capitalization means that even modest changes in expectations for future clinical or commercial milestones can translate into sizable percentage moves in IPSC stock, both upward and downward.

Stock price and investor takeaway

Century Therapeutics stock closed at USD 1.86 on the Nasdaq on September 16, 2026, down 6.06% from the previous session and corresponding to a market capitalization of about USD 336.8 million in USD terms at that date.